Alemtuzumab preconditioning with tacrolimus monotherapy - The impact of serial monitoring for donor-specific antibody

Transplantation

Volumn 85, Issue 8, 2008, Pages 1125-1132

  Shapiro, Ron ^a   Zeevi, Adriana ^a   Basu, Amit ^a   Tan, Henkie P ^a   Kayler, Liise K ^b   Blisard, Deanna M ^a   Thai, Ngoc L ^a   Girnita, Alin L ^a   Randhawa, Parmjeet S ^a   Gray, Edward A ^a   Marcos, Amadeo ^a   Starzl, Thomas E ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF FLORIDA HEALTH JACKSONVILLE   (United States)

Author keywords

Antibodies; Kidney transplantation; Outcome

Indexed keywords

ALEMTUZUMAB; CREATININE; DIPHENHYDRAMINE; FAMOTIDINE; HLA ANTIBODY; IMMUNOGLOBULIN; IMMUNOGLOBULIN G ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PARACETAMOL; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; AGED; ARTICLE; BK VIRUS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DELAYED GRAFT FUNCTION; DIABETES MELLITUS; DRUG DOSE REDUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HUMAN TISSUE; IMMUNOLOGICAL MONITORING; KIDNEY ALLOGRAFT; KIDNEY BIOPSY; KIDNEY DONOR; KIDNEY FUNCTION; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MONOTHERAPY; PLASMAPHERESIS; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOANTIBODIES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; TACROLIMUS; TISSUE DONORS; TRANSPLANTATION CONDITIONING;

EID: 42549117196     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31816a8a6d     Document Type: Article

References (19)

1. Waldmann H. A personal history of the CAMPATH-1H antibody. Med Oncol 2002; 19(suppl): 3.
2. Calne R, Friend P, Moffatt S, et al. Prope tolerance, perioperative campath 1H, and low-dose cyclosporine Monotherapy in renal allograft recipients. Lancet 1998; 351: 1701.
3. Stuart FP, Leventhal JR, Kaufman DB. Alemtuzumab facilitates prednisone free immunosuppression in kidney transplant recipients with no early rejection. Am J Transplant 2002; 2(suppl): 397.
4. Knechtle SJ, Pirsch JD, H Fechner J Jr, et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am J Transplant 2003; 3: 722.
5. Kirk AD, Hale DA, Mannon RB, et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation 2003; 76: 120.
6. Shapiro R, Basu A, Tan H, et al. Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with thymoglobulin or Campath. J Am Coll Surg 2005; 200: 505.
7. Shapiro R, Ellis D, Tan HP, et al. Antilymphoid antibody preconditioning and tacrolimus monotherapy for pediatric kidney transplantation. J Pediatr 2006; 148: 813.
8. Tan HP, Kaczorowski DJ, Basu A, et al. Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy. Am J Transpl 2006; 6: 2409.
9. Mao Q, Terasaki PI, Cai J, et al. Extremely high association between appearance of HLA antibodies and failure of kidney grafts in a five-year longitudinal study. Am J Transpl 2007; 7: 864.
10. Girnita A, McCurry K, Iacono A, et al. HLA-specific antibodies are associated with high-grade and persistent-recurrent lung allograft acute rejection. J Heart Lung Transplant 2004; 23: 1135.
11. Pei R, Lee J, Chen T, et al. Flow Cytometric Detection of HLA Antibodies Using a Spectrum of Microbeads. Human Immunol 1999; 60: 1293.
12. University of Pittsburgh Institutional Review Board (homepage on the internet). Jurisdiction, structure, and responsibilities of the Institutional Review Board. Reference manual for the use of human subjects in research. Pittsburgh, University of Pittsburgh 2006 [updated January 17, 2006; cited February 2006.] Available at: http://www.irb.pitt.edu/manual/preface.pdf.
13. Starzl TE, Zinkernagel R. Transplantation tolerance from a historical perspective. NATURE reviews. Immunology 2001; 1: 233.
14. Shapiro R, Jordan ML, Basu A, et al. Kidney transplantation under a tolerogenic regimen of recipient pretreatment and low- dose post-operative immunosuppression with subsequent weaning. Ann Surg 2003; 38: 520.
15. Meier-Kriesche HU, Schold JD, Srinivas TR, et al. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transpl 2004; 4: 378.
16. Montgomery RA, Zachary AA. Transplanting patients with a positive donor-specific crossmatch:Asingle center's perspective. Pediatr Transplant 2004; 8: 535.
17. Mizutani K, Terasaki P, Hamdani E, et al. The I Importance of anti-HLA-specific antibody strength in monitoring kidney transplant patients. Am J Transpl 2007; 7: 1027.
18. Pascual M, Saidman S, Tolkoff-Rubin N, et al. Plasma exchange and tacrolimus- mycophenolate rescue for acute humoral rejection in kidney transplantation. Transplantation 1998; 66: 1460.
19. Kowalski R, Post D, Schneider MC, et al. Immune cell function testing: An adjunct to therapeutic drug monitoring in transplant patient management. Clin Transplant 2003; 17: 77.